The recent Government Accountability Office report into the direct-to-consumer genetic testing industry certainly made a splash: it took centre stage at a Congressional hearing on the industry, and garnered media headlines about "bogus" results being generated by testing companies.
As I noted at the time of its release, the report is an obscenely one-sided affair: it's transparently framed as an attack piece rather than a balanced analysis of the state of the industry. That's a real shame, because the information collected by the GAO could so easily have been used to provide valuable insight into the industry, and to guide careful regulation that addresses the deficiencies of current tests without punishing innovators.
Over at Genomes Unzipped I have a post up with Luke Jostins and Kate Morley pointing out just how much of a tragically missed opportunity the GAO report represents: for a project that cost US tax-payers $30,000 in testing kits alone, it fails to capitalise on any of the data it collected or the expertise it consulted, and instead resorts to grand-standing and vitriol.
Over the next couple of weeks we'll be seeing what we can do to get access to the full transcripts and data used by the GAO for their report. To find out how that goes, keep an eye on Genomes Unzipped.
- Log in to post comments
More like this
(This is an edited excerpt from an op-ed piece I just wrote for Xconomy, posted here as I think it provides some nuance on my views on regulation of genetic testing that was lacking from my post last week.
Some context for new readers: a Congressional investigation into the direct-to-consumer (DTC…
This week was pretty hectic, so there were plenty of useful or interesting links from the personal genomics world that I didn't have time to write about in detail. Feel free to share your own suggestions in the comments.
Responses to the Congress/FDA crack-downAs all of you will be aware, the big…
(Cross-posted to Genomes Unzipped.)
Today's US Congress Committee on Energy and Commerce hearing into the direct-to-consumer genetic testing industry was a vicious affair. Representatives from testing companies 23andMe, Navigenics and Pathway faced a barrage of questions about the accuracy and…
The brief Golden Age of direct-to-consumer genetic testing - in which people could freely gain access to their own genetic information without a doctor's permission - may be about to draw to a close. In a dramatic week, announcements of investigations into direct-to-consumer genetic testing…